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Pounds (GBP). Cost of improved preservation technique was not
included in the model. RESULTS: IPTx may generate 4.18 and
1.19 QALY gain vs MM and CPTx respectively by increasing
heart transplantation rates and reducing the impact of CIT.
Treatment costs are reduced by 4476 GBP vs MM and increased
by 5768 GBP vs CPTx. CONCLUSION: Many patients die
on the waiting list due to the lack of transportability of hearts
from eligible donors. Improved preservation of explanted hearts
may generate 58′496 GBP of economic value per each heart
transplantation.
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OBJECTIVES: To assess the effects of various lipid-modifying
strategies on direct medical costs of coronary heart disease
(CHD) events among a representative patient cohort with estab-
lished CHD. METHODS: Model-based analysis, using data from
clinical trials, published literature, and national databases to
project CHD medical costs (emergency, inpatient, and outpa-
tient) over 5 years. The analysis focused on hypothetical cohorts
of 10,000 CHD patients (50 years of age or older) with any
abnormal lipid parameter (LDL-C, HDL-C, Non-HDL-C, and/or
TG). The expected number of CHD events was calculated using
the Framingham Heart Study equation for secondary prevention.
Age, sex, and coronary risk-factor data for patients with CHD
were obtained from a nationally-representative US health survey.
Direct medical costs were expressed in $US 2006, discounted
annually at 3%. The drugs of interest included simvastatin (S)
alone and ﬁxed-dose extended release niacin/simvastatin (ERN/
S), allowing an evaluation of increasing doses of S or adding a
second agent to S. RESULTS: Direct medical costs of CHD events
over 5 years are estimated to be approximately $3436 per patient
for patients treated with 20 mg of S. These costs would decrease
by 8.8% with 1000/20 mg of ERN/S. Compared to more aggres-
sive lipid therapy with 40 mg of S, 1000/40 mg of ERN/S would
decrease CHD costs by 9.1%. Relative to a maximum dose of
80 mg of S, the maximum dose of ERN/S (2000/40 mg) would
reduce CHD event costs by 11.2%. CONCLUSION: Intensifying
lipid-modifying therapy with ﬁxed-dose ERN/S combinations
would further reduce direct medical costs of CHD events more
effectively than S monotherapy in a secondary prevention popu-
lation. Further research on the cost-effectiveness of intensifying
dyslipidemia treatment is warranted.
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PATIENTS WITH CONGESTIVE HEART FAILURE
Bharmal M1, Zyczynski T2, Linnstaedt A1, Kennedy L3, Gemmen EK1
1Quintiles Strategic Research & Safety, Falls Church,VA, USA, 2GE
Healthcare, Princeton, NJ, USA, 3GE Healthcare, Buckinghamshire, UK
OBJECTIVES: Examine gender differences in resource use,
expenditures and mortality among U.S. Medicare patients fol-
lowing discharge from a hospital admission for congestive heart
failure (CHF). METHODS: Analyses were conducted on
national 5% sample of Medicare claims from January 1999 to
December 2001. A cohort that had an initial hospitalization with
a primary diagnosis of CHF was identiﬁed. Resource use at one
year preceding and following the initial CHF admission was
compared among males and females. Separate multivariate
regression models were developed by gender to assess the factors
associated with outcomes. Models included variables for patient
characteristics, comorbidity, compliance with routine care and
resource use in the year prior to CHF admission. RESULTS: A
majority of the 34,540 CHF patients were white (86%), one-half
were 80 years or older and approximately 58% were female.
Male CHF patients had a higher Charlson comorbidity score
compared to females (4.27 vs. 3.99; p < 0.0001). Females were
more likely than males to have an inpatient readmission within
365 days (58.6% vs. 41.2%; p = 0.016), an emergency depart-
ment visit within 180 days preceding (58.3% vs. 41.7%;
p = 0.0019) and following CHF admission (57.7% vs. 42.3%;
p = 0.035), physician ofﬁce visits within 365 days preceding
(58.5% vs. 41.5%; p = 0.0001) and following CHF admission
(57.7% vs. 42.3%; p = 0.0001). Females were also more likely
than males to die within 60 days (56.3% vs. 43.7%; p = 0.009),
90 days (56.5% vs. 43.5%; p = 0.006), 180 days (56.2%
vs. 43.8%; p = 0.0001) and 365 days (56.1% vs. 43.9%;
p < 0.0001) of the initial CHF admission. In multivariate models,
factors associated with health care resource use, expenditures
and mortality had similar trends in both gender models. CON-
CLUSION: There appears to be gender differences in resource
use and outcomes among CHF patients. Effort to better target
interventions, diagnostic and therapeutic, among patients
at higher risk of adverse outcomes carries potential for cost-
effective management of CHF patients.
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OBJECTIVES: Determine hypertension-related costs and cost-
effectiveness ratios of pharmaceutical treatment for patients with
hypertension in Greece METHODS: Data was derived from the
PharmacoECOnomic Assessment of Prognostic Risk Occupa-
tional Survey (ECON-APROS), a cross-country prospective
study. The sample included individuals 30–75 yrs old, diagnosed
with hypertension (Systolic Blood Pressure >140 mmHg and/or
Diastolic Blood Pressure >90 mmHg), who were treated and
monitored for a period of 1 year after the diagnosis. Patients
were separated in two subgroups: a) those with uncomplicated
hypertension (N = 1243) and b) those with complications e.g.
CVD, CHD, MI etc. (N = 122). Demographic, clinical and socio-
economic information was collected. Cost analysis was based on
the direct cost estimations and the measurement of the effective-
ness was based on the absolute reductions in the mean SBP for
each subgroup after 1 year of treatment. The perspective of the
Greek NHS was taken. Tariffs are referred to 2006 prices and
costs are expressed in Euros. RESULTS: Mean direct cost per
patient suffering from uncomplicated hypertension was esti-
mated at 687€ per year while for the second subgroup was
signiﬁcantly higher at 1771€ per year. Mean reduction in the
patients’ Systolic Blood Pressure was 32.58 mmHg for the ﬁrst
subgroup and 34.38 mmHg for the second. Cost-effectiveness
ratios for each subgroup were estimated at 21.1€/mmHg and
51.7€/mmHg, respectively, for every 1 mmHg lowering of the
Systolic Blood Pressure. CONCLUSION: The long term conse-
quences of untreated hypertension are both life-threatening, for
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the patients, as well as resource-consuming for the health care
system. The ECON-APROS study has demonstrated that, besides
the importance clinical-wise to treat hypertensive patients in their
early stages of the disease, it is also cost-effective for the Greek
health care setting
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is a rare
progressive and severe disease with short life expectancy. Bosen-
tan has been shown to slow PAH progression and improve func-
tional status, quality of life, and survival. The objective of the
study is to assess cost effectiveness of bosentan for the treatment
of PAH from a health care payer’s perspective in South Korea.
METHODS: A Markov model was used to estimate the expected
life years, quality-adjusted life years (QALYs) and costs for a
hypothetical cohort of 100 PAH patients treated for one year
with bosentan compared to iloprost. The health states included
in the model were WHO functional class I to IV and death.
Transition probabilities were calculated based on observed tran-
sitions for bosentan and iloprost. Utility values were borrowed
from an existing study, of which the utilities were calculated from
estimated EuroQol health states. Costs were comprised of medi-
cation, hospitalization, and monitoring. Medication and moni-
toring costs were estimated from the National Health Insurance
reimbursement data, with the latter based on expert opinion
while hospitalization costs were estimated from a teaching hos-
pital’s claims data for 13 patients. RESULTS: The model pre-
dicted that the expected life years of 100 PAH patients would be
98.5 years with bosentan and 98.4 years with iloprost while the
expected QALYs would be 51.1 QALYs and 33.1 QALYs, respec-
tively. The estimated costs would be 3,395 million KRW with
bosentan and 8,618 million KRW with iloprost. Treatment with
bosentan compared to treatment with iloprost resulted in a
greater gain in QALYs, though little gain in life years, with a
signiﬁcant cost saving. These ﬁndings were not substantially
affected by adjustments of transition probabilities, utility values,
or price of bosentan. CONCLUSION: Bosentan is more cost-
effective or cost-saving than iloprost for the treatment of PAH in
South Korea.
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OBJECTIVES: Acute decompensated heart failure (AHF) is a
leading cause of hospital admission. The Randomized EValua-
tion of Intravenous LeVosimendan Efﬁcacy (REVIVE II) trial
compared patients randomly assigned to levosimendan (levo) or
placebo (SOC), each in addition to local standard AHF treat-
ments. We report the REVIVE II economic analysis. METHODS:
REVIVE II enrolled patients (N = 600) hospitalized for AHF
remaining dyspneic at rest despite treatment with intravenous
diuretics. Case report forms documented index hospital treat-
ment (drug administration, procedures, days by care unit) as well
as subsequent admissions during 90 day follow-up. These data
were used to impute cost based on an econometric cost function
derived from >100,000 AHF hospital billing records selected per
REVIVE II inclusion criteria. RESULTS: Index admission mean
length of stay (LOS) was shorter for the levo group compared
with standard of care (SOC) (6.8 vs. 8.7 days, p = 0.007)
although ICU/CCU days were similar (levo 2.9, SOC 3.2,
p = 0.81). Excluding cost for levo, predicted mean (median) cost
for the index admission was levo $13,590 (9,458), SOC $19,021
(10,692) with a difference of $5,431 (1,234) favoring levo
(p = 0.04). During follow-up through end of study day 90,
no signiﬁcant differences were observed in hospital admis-
sions (p = 0.67), inpatient days (p = 0.81) or emergency visits
(p = 0.41). Subset analysis excluding patients with low baseline
blood pressure also showed lower cost for the index admission
for the levo group. Assuming an average price for levo in coun-
tries where is currently approved, incremental cost-effectiveness
of levo relative to SOC in this subset is less than $1000 per year
of life gained—a value well below accepted thresholds. CON-
CLUSION: In REVIVE II, patients treated with levo had shorter
LOS and lower cost for the initial hospital admission relative to
patients treated with SOC. When administered in accordance
with the current label, levo is highly cost-effective relative to
SOC.
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OBJECTIVES: Several drugs demonstrated the ability to reduce
cardiovascular events incidence in secondary prevention. Among
them we have aspirin, statins, beta-blockers and ACE-inhibitors.
We performed a cost effectiveness analysis of several therapeutic
options to assess their relative pharmacoeconomic performance.
METHODS: We built a Markov model to simulate the survival
rate and the cardiovascular events frequency in a high cardiovas-
cular risk cohort formed by Italian patients who already had
an acute myocardial infarction. Secondary prevention strate-
gies considered were: C—standard therapy; R—ramipril plus
standard therapy; S—simvastatin plus standard therapy;
P—pravastatin plus standard therapy; R + S—ramipril and sim-
vastatin plus standard therapy; R + P—ramipril and pravastatin
plus standard therapy. Treatment efﬁcacy values were based on
the ﬁndings of the HOPE study for ramipril, the HPS study for
simvastatin, the LIPID, WOSCOPS and CARE for pravastatin.
Time horizon of the simulation was cohort lifetime. Direct sani-
tary costs were considered and valued according to current
national prices, tariffs, and published literature. RESULTS: The
average life expectance resulted from the simulation was 12.0
in C, 12.9 in R, 12.7 in S, 13.1 in P, 13.6 in R + S and 14.0 in
R + P strategies. The incremental cost effectiveness ratios
(ICERs) with respect to C strategy were 1241 Euro/Life Year
(LY) in R, 7610 Euro/LY in S, 7315 Euro/LY in P, 4660 Euro/LY
in R + S and 5192 Euro/LY in R + P strategies. CONCLUSION:
The simulation showed that the associations between ramipril
and statins are the most effective strategies. From the economic
standpoint ramipril alone is largely the most cost-effective strat-
egy. This is mainly due to the lower cost of the drug with
respect to statins.
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